It’s good therapy to think out loud! Quite honestly treading water is his speciality. Yes it is virtually impossibly for life science to raise money if they have zero income. We don’t even have a product until they find a drug developer to utilise the theory. Bit of a catch 22 here.
Exactly my first thought Wully. Nige wants to know how likely I would be to recommending n4 to a
Friend as an investment. Nigel I want to keep my friends. How close are we to a deal? Then I’ll tell you if there was a dogs chance of recommending to a friend. Fully expect the market to pass on this non news. I don’t think Nige is as naive as he makes out which is a worry. On the other hand the nanogenics deal looks a blinder as long as this doesn’t turn into another endless university project. He doesn’t need to convince investors he needs to convince the market, then investors will come running
The trades in this stock never make any sense. Record revenue and two months to add to it. The sp his half the price it was when revenue was possibly 20 million less! If it dips below 40p I’ll be there waiting
The dark and murky world of trades in Insewincey. Looks like a series of buying but the shares still manage to go down . If todays trades were actually sells then the so would be back to old price of about 5p. Managed to get an offer of 63p for the remains of my holdings. This is just the most dodgy stock on the market.
Can’t see any sign of Meatly for sale in uk. Yet another Mellon broken promise like Blunalu that was supposed to be on the market 2 years ago. How on earth Mellon can justify his fees I don’t know. Obviously that in itself is a big disincentive to invest here.
Mad dog. Vox markets is well worth following. Paul Hill does good interviews with Harwood fund manager Chris Mills and also great interview with Stella Asset management.. mills is an expert stock picker and also sits/advises on a few boards in directorial capacities. Remember they are only analysing companies and disclosing positions. Not advising to buy anything. That’s up to you.. gl
Its is definitely a punt. Very chequered history. I dont know if we will ever get the full story on this company. The risk reward seems very stretched. This is a crowded sector with Hsbc muscling back in with Zing at the beginning of the year. Too much infighting for my liking. It doesnt seem to bode well with investors and it looks like it doesnt bode well with clients. Why would you with plenty of competition to choose from. Champagne Charlie’s going to have to get used to Prosecco at best.
These so called ‘professional ‘ research sites never seem able to keep up with events. Stickopedia ( who charge a basic £250 for just uk stocks) are so slow. They still have last years revenue of £18 million , when they latest actual information suggests revenue of 30 million. Lse cant even get RNS flowing. Its no wonder the uk is still in the doldrums compared to other markets. It seems to me we will continue to rely on takeovers to realise value in uk , which of course means selling GB on the cheap, just like Gordon Brown did when he sold off our gold reserves at €250 an ounce. The genius economist!
Fortunately zero is the lowest it can go. October 2023 it went to .65p if people think it’s worth selling at this price it’s their 📞. Don’t see the point myself. A director bought a junk recently. We know they can can survive to prospective clinical trials for Nanogenics in 2025. We know at least three universities are conducting research for N4p. Quite why Nigel made so obvious he was testing the water for another possible raise at this stage I don’t know or for how much. Aside from all that there is the possibility of a partnership announcement . The trouble is, is that likely to happen pre clinical trials? The report was pretty emphatic about the advantages their drug delivery technology can make to the treatments of aggressive disease.
Not to mention exercise of options last week . Unbelievable! Actually it’s how this stock market works
Expecting a big hike in revenue already upgraded and now another key appointment . This is getting seriously interesting. No doubt the dosey market will acknowledge in their own good time
Definitely on more people’s radar since NED appointments. Half next years revenue already in the bag. News still to come from Monument in which they have a 25 per cent stake having been spun out from Cog. The dots are definitely lining up. It’s almost like the market has valued the acquisitions at zero. This often the case in the market at the moment. Of course this stock is a little illiquid so is very volatile. Let’s hope it gets volatile in an upward move this year
Unfortunately a company that keeps taking from investors to reward the directors. So typical of dross segment of Aim
News flow just keeps flowing. Attendance by CNC at embedded tech forum in USA and news of ‘TNS’ for vehicle architecture’
Unfortunately the markets feel pretty strange right now. Very mixed signals. ‘A rapid rise out of mild recession’ ? Certainly a lot of volatility across the board. I have been in Melbourne for last two months where the economy is extremely buoyant, although property has cooled a little. I met someone from a life science company the other evening and they were very bullish about biotech, agreeing we are on the cusp of some massive advances in medicines . Feel quite a bit more hopeful with N4p but obviously still highly risky. Gl all.
It’s not the private investor that’s going to get this noticed. There are plenty of stocks that just don’t get the investors eye, especially at a time when money is sitting on the fence. What does amaze me is how little notice the medical and drug development industry seems to be taking. The competition just in nano tech is fierce and the big money is in USA. The dots do appear to be aligning slowly, mostly in university labs it would appear at the moment. A well established drug company is where the next big leap has to come from.
Eck often seems to be the subject of mysterious big late reported trades ending the day with various different closing prices. The consensus seems to be 41.80p price will out in the end!
Highly recommend looking at the EpiVax website. Whether this is report is a commission or endorsement it is the best piece of news I have read about N4p. It almost worries me that there has been so little reaction to it. Why anyone would sell now is also quite weird. Any way new hope for holders and cancer sufferers. They must succeed.
At last some meaningful news. An email of a report that concludes that Nuvec could help the treatment of ‘refactory cancer’, a cancer that is resistant to either the beginning of conventional treatment or becomes resistant to repeated conventional treatments. The report should help progress towards clinical trials
As happens with many companies listed on AIM, they lose 90 percent or more of their value from listing , especially when they have no revenue and continually rely on placings to stay afloat. The advantage of being listed was shown when N4p was able to raise funds to buy Nanogenics recently, who not being listed could not raise the money they needed to stay afloat. This provides opportunities for listed companies to add T bargain prices. Don’t k ow why Nigel feels the need to RNS every single patent news. It’s hardly price sensitive news and they have a website and now an investor hub. Price sensitive news is when they start making money or get a partner.